Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AE-941 in Addition to Combined Modality Treatment for Locally Advanced Unresectable Non-Small Cell Lung Cancer
NCT00005838Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- Feb 2007
- Modality
- Biologic, Angiogenesis inhibitor, Metalloprotease inhibitor
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Arm I (AE-941) with Arm II (Placebo) (2 arms). Primary endpoint: Overall Survival up to 7 years. Started Mar 2000; status: completed.
02
Drugs
Neovastat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00005838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005838.